Torii Pharmaceutical Co Ltd
TSE:4551

Watchlist Manager
Torii Pharmaceutical Co Ltd Logo
Torii Pharmaceutical Co Ltd
TSE:4551
Watchlist
Price: 4 695 JPY -0.74% Market Closed
Market Cap: 135.2B JPY
Torii Pharmaceutical Co Ltd
/
Cash Flow Statement
/
Cash from Operating Activities

Torii Pharmaceutical Co Ltd
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Torii Pharmaceutical Co Ltd
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Torii Pharmaceutical Co Ltd
TSE:4551
Cash from Operating Activities
¥3.6B
CAGR 3-Years
N/A
CAGR 5-Years
-39%
CAGR 10-Years
12%
Takeda Pharmaceutical Co Ltd
TSE:4502
Cash from Operating Activities
¥1.1T
CAGR 3-Years
-1%
CAGR 5-Years
13%
CAGR 10-Years
16%
Daiichi Sankyo Co Ltd
TSE:4568
Cash from Operating Activities
¥8.8B
CAGR 3-Years
-62%
CAGR 5-Years
-47%
CAGR 10-Years
-24%
Otsuka Holdings Co Ltd
TSE:4578
Cash from Operating Activities
¥354.6B
CAGR 3-Years
16%
CAGR 5-Years
13%
CAGR 10-Years
7%
Chugai Pharmaceutical Co Ltd
TSE:4519
Cash from Operating Activities
¥327.1B
CAGR 3-Years
5%
CAGR 5-Years
10%
CAGR 10-Years
24%
Astellas Pharma Inc
TSE:4503
Cash from Operating Activities
¥165.4B
CAGR 3-Years
-17%
CAGR 5-Years
-6%
CAGR 10-Years
-2%

Torii Pharmaceutical Co Ltd
Glance View

Market Cap
132B JPY
Industry
Pharmaceuticals

Torii Pharmaceutical Co., Ltd. engages in the manufacturing and marketing of pharmaceutical products. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 560 full-time employees. The company went IPO on 2013-10-01. The Company’s main product categories include oral pruritus improving agents, proteolytic enzyme inhibitors, hyperkalemia improving agents, topical adrenocortical hormones, allergen immunotherapy for cedar pollinosis, allergen immunotherapy for mite allergy, active viable bacterial preparations, uterine contraction inhibitors in premature birth and others. The Company’s main products include Remitch, Riona tablets, Keixalate, Yulinome tablets, Antebate, Locoid, Zefnate, Sida Torengi pollen sublingual solution, Miticure mite sublingual tablet, Biosley, Magcent and others.

Intrinsic Value
4 736.45 JPY
Undervaluation 1%
Intrinsic Value
Price
What is Intrinsic Value?

See Also

What is Torii Pharmaceutical Co Ltd's Cash from Operating Activities?
Cash from Operating Activities
3.6B JPY

Based on the financial report for Dec 31, 2024, Torii Pharmaceutical Co Ltd's Cash from Operating Activities amounts to 3.6B JPY.

What is Torii Pharmaceutical Co Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
12%

Back to Top
ALPHA SPREAD
Follow us
Join more than 242,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.